CJC-1295 (+DAC)
Modified Growth Hormone-Releasing Factor (1-29) with Drug Affinity Complex (DAC)
CJC-1295 with DAC (Drug Affinity Complex) is a modified synthetic 30-amino-acid analogue of growth hormone-releasing hormone (GHRH 1-29). It features specific amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) designed to resist enzymatic degradation, coupled with a reactive maleimidopropionic acid moiety at its C-terminal lysine residue. This chemical architecture facilitates covalent binding to endogenous serum albumin in research models, significantly extending its biological half-life. In experimental laboratory settings, the peptide provides a continuous stimulus to anterior pituitary somatotrophs, resulting in prolonged elevations of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels. Unlike short-acting secretagogues, CJC-1295 with DAC supports research into chronic neuroendocrine regulation while preserving physiological pulsatile secretion characteristics. This material is provided as a purified, lyophilized solid strictly intended for in vitro cellular assays and in vivo laboratory animal research exploring somatotropic signaling, metabolic modulation, and bioconjugate pharmacokinetics.
Choose how to buy
Subscribe & save 5% on reshipsYour first order ships at the regular price. Every reship after that is 5% off. Pause, change the interval, or cancel anytime.
- Purity
- ≥99%
- Form
- Lyophilized powder
- CAS Number
- 863288-34-0
- Molecular Formula
- C152H252N44O42
- Molecular Weight
- 3647.28 g/mol
- Available sizes
- 5mg
Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Maleimidopropionyl)-NH2
Mechanism of Action
CJC-1295 with DAC functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR) on anterior pituitary somatotrophs. Binding stimulates the Gs protein-coupled receptor cascade, elevating intracellular cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA). This signaling pathway opens voltage-dependent calcium channels, facilitating the gene transcription and secretory release of endogenous growth hormone. The integrated Drug Affinity Complex contains a maleimide group that selectively binds to free thiol groups on circulating albumin (primarily cysteine-34). This bioconjugation shields the core peptide from rapid renal filtration and enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase (NEP), extending receptor engagement from minutes to multiple days in test subjects.
Research Areas
- ●Pituitary somatotroph receptor kinetics
- ●Long-acting peptide bioconjugation and pharmacokinetics
- ●Endocrine regulation of systemic IGF-1 production
- ●Adipocyte lipolysis and cellular metabolism models
- ●Musculoskeletal tissue repair and protein synthesis pathways
Selected References
- Teichman SL et al., J Clin Endocrinol Metab (2006)
- Jette L et al., Endocrinology (2005)
- Alba M et al., Am J Physiol Endocrinol Metab (2006)
Related Products
